Compare OZ & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | ACHV |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 233.2M |
| IPO Year | 2020 | 2018 |
| Metric | OZ | ACHV |
|---|---|---|
| Price | $52.34 | $4.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 11.5K | ★ 321.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,675,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.68 | N/A |
| 52 Week Low | $48.50 | $1.84 |
| 52 Week High | $75.73 | $6.03 |
| Indicator | OZ | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 43.39 |
| Support Level | $52.02 | $3.93 |
| Resistance Level | $64.85 | $4.30 |
| Average True Range (ATR) | 1.05 | 0.23 |
| MACD | 0.48 | -0.00 |
| Stochastic Oscillator | 85.13 | 16.31 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.